# FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy

> **NCT05662488** · — · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 25 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- Bile Duct Cancer

## Interventions

- **DIAGNOSTIC_TEST:** [68Ga]FAPI PET/CT and [18F]FDG PET/CT

## Key facts

- **NCT ID:** NCT05662488
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2022-08-30
- **Final completion:** 2023-08-30
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662488, "FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05662488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*